Study Comparing Two Ovarian Stimulation Methods for Women Undergoing Fertility Preservation or Genetic Testing

What this Trial Is About

Researchers are conducting a phase 4, randomized, prospective study with a crossover design to compare patient satisfaction and treatment adherence between two types of ovarian stimulation for IVF. The study focuses on women undergoing elective fertility preservation or pre-implantation genetic testing for aneuploidy PGT-A. It also examines differences in hormonal responses and ovarian reactions between corifollitropin alfa with progestin-primed ovarian stimulation CFAPPOS and conventional recombinant FSH with a GnRH antagonist cycles. Participants will receive both treatments in a crossover fashion. One treatment cycle involves a single injection of corifollitropin alfa combined with progestin tablets, while the other involves multiple injections of recombinant FSH and GnRH antagonist drugs. The study drugs include Elonva, Puregon, Orgalutran, Gonapeptyl, and Cerazette. Each participant will experience both stimulation protocols, allowing direct comparison within the same individual. Women enrolled will be monitored over six months, filling out questionnaires to assess quality of life and satisfaction with each treatment. Researchers will also track ovarian response and hormone levels during each stimulation cycle. Participants must complete questionnaires before, during, and after treatments. The study aims to collect detailed endocrine data and evaluate treatment preferences to improve patient-centered IVF approaches.

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study